Alcon launches QD NSAID for post-cataract surgery pain, inflammation

Fort Worth, TX-Alcon Laboratories Inc. has launched Ilevro (nepafenac ophthalmic suspension) 0.3%, a QD non-steroidal anti-inflammatory drug (NSAID) drop for treating pain and inflammation associated with cataract surgery.

In two double-masked, randomized clinical trials, Ilevro suspension demonstrated superior clinical efficacy compared to its vehicle, according to the company. Patients treated with Ilevro were less likely to have ocular pain and measurable signs of inflammation-cells and flare-at the end of treatment than those treated with its vehicle. (1)

Patients administered Ilevro experienced superior outcomes when compared to those on vehicle in these areas:

• Inflammation resolved at Day 14 in 65% of Ilevro patients vs. 32% of patients on vehicle. (1)

• Pain resolution rates in Ilevro patients were 86% compared to 46% of patients on vehicle. (1)

The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. These reactions occurred in approximately 5 to 10% of patients, according to investigators.

Reference:

1. Ilevro Prescribing Information. Alcon Laboratories, Fort Worth, TX.